505031-07-2

Upstream product

• 59074-26-9 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 
• 4108-90-1 piperidine-1-sulfonamide 
• 1207386-65-9 methyl 3-(4-chlorophenyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carbothioimidate 
• 505031-19-6 piperidine-1-sulfonic acid [3-(4-chloro-phenyl)-4-phenyl-4,5-dihydro-pyrazole-1-carbothioyl]-amide 
• 505031-18-5 piperidine-1-sulfonyl isothiocyanate 
• 505031-17-4 Piperidine-1-sulfonic acid 1-[3-(4-chloro-phenyl)-4-phenyl-4,5-dihydro-pyrazol-1-yl]-1-methylsulfanyl-meth-(Z)-ylideneamide 
• 74-89-5 methylamine 

Relevant academic research and scientific papers

An expedient atom-efficient synthesis of the cannabinoid CB1 receptor inverse agonist ibipinabant

A novel synthetic route to the highly selective and orally active cannabinoid CB1 receptor inverse agonist ibipinabant is described which combines the use of inexpensive, commercially available reagents and mild reaction conditions with a high

SYNTHESIS OF 3,4-DIARYL-4,5-DIHYDRO-(1H)-PYRAZOLE-1- CARBOXAMIDINE DERIVATIVES

The invention relates to a novel chemical route to 3,4-diaryl-4,5-dihydro-(1H)-pyrazole-1-carboxamidine derivatives, known as potent cannabinoid-CB1 receptor antagonists, and to novel intermediates of these compounds. The synthetic route produced considerably higher yields than those reported, without the use of corrosive reagents. The process concerns the preparation of a compound of formula (I) wherein the symbols have the meanings given in the description.

Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity

Novel 3,4-diarylpyrazolines 1 as potent CB1 receptor antagonists with lipophilicity lower than that of SLV319 are described. The key change is the replacement of the arylsulfonyl group in the original series by a dialkylaminosulfonyl moiety. Th